Inventurus Knowledge Solutions Q2 FY27 Earnings Call: Revenue Up 104% on TruBridge Consolidation, Early-to-Mid-30s% Margin Path Reiterated (IKS)

First Post-Acquisition Quarter: Consolidated Numbers In Line

• Revenue of Rs.1,592 Cr (~Rs.1,592.5 Cr) — up ~104% YoY and ~78% QoQ in rupee terms, reflecting the first consolidated quarter with TruBridge (82 days of consolidation); constant-currency revenue was ~$169 million.
• EBITDA of Rs.442 Cr at a 28% margin — in line with management expectations despite ~Rs.25 Cr of one-time TruBridge integration expenses; adjusted EBITDA was Rs.459 Cr adding back Rs.17.5 Cr of ESOP expense.
• PBT of Rs.273 Cr (~20% YoY), PAT of Rs.217 Cr — adjusted PAT (ex-ESOP and intangible amortization) at Rs.273 Cr (~17% of revenues, ~36% YoY); EPS at Rs.13 (~20% YoY, in line with PAT growth).
• Legacy IKS revenue of ~$101 million — up a little over 13% YoY in USD terms, an improvement over Q1 FY 2026-2027; legacy TruBridge contributed ~$68 million against the ~$75 million/quarter ($300 million annualized) run-rate baseline cited at deal announcement.
• Adjusted OCF of Rs.393 Cr (~90% of EBITDA) — reported cash flow was Rs.96 Cr lower due to the TruBridge acquisition expense paid after the consolidation cutoff (non-recurring), and Q2 FCF carried ~Rs.50 Cr of one-time higher tax, a timing item to be consumed over the remaining two quarters of FY 2026-2027.
• IKS is now a nearly $700 million annual run-rate company — vs ~$150 million in October 2023 pre-IPO, ~5x in 3 years, significantly inorganic and achieved with no equity dilution.
• Management explicitly repeated that no formal guidance is being given; growth and margin figures cited are ambitions/expectations, not guidance.

Tracking Ahead of Outside-In Assumptions, But Synergies Still Early

• Integration tracking ahead of assumptions — based on 50+ customer meetings; 3 of TruBridge's top 5 executives took combined-entity roles (Chris Fowler as chief strategy officer, Amaris as global CHRO, David Harse as GM of the EHR business); the EHR base is "even stickier than we had imagined."
• Patient-record access at 3.5-4x the 5 million assumed at announcement — management says this significantly enhances its proprietary AI training moat; early synergy review suggests IKS can beat its own synergy expectations.
• Implied TruBridge margin above deal assumptions — analyst back-calculation (Vibhor Singhal/Nuvama) suggested ~17.5% adjusted EBITDA; CEO Sachin Gupta indicated ~21-22% for Q2 FY 2026-2027 on an adjusted basis, vs the 14% contemplated at acquisition.
• No material synergies realized yet at ~82 days post-acquisition — removal of public company costs was already factored into the $68 million run rate; management deliberately avoided interventions for at least the first 3 months; only non-material savings from natural attrition and reduced advisor costs.
• Three synergy vectors to play out from H2 Q3 FY 2026-2027 onwards — restructuring the financial health RCM operating model, similar interventions on medical coding, and integration of the two SG&A organizations; CFO expects more synergies through Q3-Q4 FY 2026-2027 and into FY29.
• White space in the install base — 600+ hospitals run on the TruBridge EHR but fewer than 200 take the financial health (RCM) offering; 2 extensive customer assessments of the full platform system of action have been launched, and 2 TruBridge clients have begun assessments of bringing the entire IKS system of action to rural/community settings.
• Management will not model significant net growth in the legacy TruBridge book in FY 2026-2027, framed as a year of integration and consolidation.

Proprietary Data Moat, EHR-Agnostic Context Layer, Project Endeavor

• Acquisition rationale centers on proprietary data — CEO Sachin Gupta called the TruBridge EHR's millions of patient records a "treasure trove" to be translated into AI training data for a context layer, so IKS is not dependent on external frontline commercial models for everything.
• EHR-agnostic system of intelligence under construction — a data architecture moves EHR data into a staging area feeding task-specific intelligence systems (prior auth, denial prediction/prevention, coding); knowledge graphs for coding are already built, with specialty-specific graphs in progress.
• Three system-of-action categories to be integrated into the TruBridge EHR — denial prediction and prevention, medical coding (with parts becoming autonomous), and ambient clinical documentation plus virtual clinical assistant; targeted to go live in the legacy COBOL-based TruBridge EHR by Q1 FY28.
• ~1-year journey to a comprehensive system of intelligence — for the entire ambulatory system of action, i.e., completing around FY 2027-2028, with more systems of action becoming "reliably agentic" so the human-in-the-loop keeps coming down.
• Project Endeavor — a ground-up AI-native operating system for the rural/community market integrating system of record and intelligence; the acute system-of-action feature set (currently 5 features vs 16 on the ambulatory side) will be expanded, growing the in-acute TAM.
• Outcome-based pricing shields AI productivity gains — CEO said customers pay for outcomes, not effort, so the bulk of productivity gains accrue to IKS's bottom line; management expects incremental price compression over time as the model becomes more AI-led and agentic, but believes it will be more than offset by retained productivity benefits.

Legacy IKS Above Industry; TruBridge Inflection Expected FY28

• Legacy IKS expected to grow above the industry's 12% on a constant-currency basis — CEO validated a framework of 13-14% (period unspecified); management has delivered better-than-industry growth consistently over the last eight quarters as a public company.
• TruBridge growth ambition of 10-12% by late FY28/early FY29 — for the $200 million system-of-action portion of the $300 million book (rural-market industry growth ~10% vs 12% overall); management explicitly stated this is an ambition, not guidance.
• System-of-record EHR book (~$100 million) has no growth ambition — management hopes to keep it relatively flat through FY28-FY29, with moderate growth possible from FY29 onwards once the new integrated AI-first operating system (Project Endeavor) is rolled out.
• By FY29, the two-thirds system-of-action book is expected to come close to legacy IKS growth — while the system-of-record third is not expected to reach that level until late FY29 or possibly FY30.
• Q2 FY 2026-2027 deal wins: 4 legacy IKS wins plus 1 TruBridge win — a major cross-sell into Augusta Health (part of the Mayo Clinic network), new logos White Wilson, Evolve (multi- and single-specialty freestanding medical groups) and UMass Memorial (large health system in greater Massachusetts); TruBridge added Mish, a specialty surgical hospital.
• TruBridge Encoder flagged as a significant cross-sell product — CFO Nitya Balasubramanian said the automated coding tool is not specific to the rural or acute market; the company committed to investing behind it and taking it to a larger customer base (period unspecified).
• Management ruled out cross-selling the TruBridge EHR into the legacy IKS physician group base, citing a highly saturated US EHR market; a selective reverse cross-sell of TruBridge's hospital (acute) RCM capabilities "might" translate into hospital owners within IKS's health system-owned physician groups.

Leverage Under 3x; Path Back to Early-to-Mid-30s% EBITDA

• Net debt of Rs.5,280 Cr (~$550 million) at end of Q2 FY 2026-2027 — vs gross debt of ~$611 million assumed at the TruBridge acquisition; already under 3x EBITDA on Q2 EBITDA of Rs.442 Cr; management hopes to pare it down via synergies and cash generation.
• Net leverage targeted to near zero by end FY30 — alongside optimism on the Rs.3,000 Cr TrueNorth revenue target for FY30; the loan is a 5-year facility with an 18-month moratorium on principal, so principal repayment should begin at end-CY2027 (Q3 FY 2027-2028).
• Interest cost guided to ~$10 million per quarter from Q3 FY 2026-2027 — at current rates (Q2 finance cost was Rs.101 Cr including ~$9 million accounted); pricing is SOFR + 2.75%, sliding to SOFR + 1.75% once leverage comes down to 1.7x (period unspecified).
• Margin reiteration — post-acquisition, management reiterated it should return to traditional early-to-mid-30s% EBITDA margins (period unspecified), while leaving timing ("sooner rather than later") open; no specific TruBridge margin guidance for FY28 or FY29, but management hopes to bring both books to early-to-mid 30s% by FY30.
• ESOP grant of ~4% of total equity to the top 60-65 leaders — approved by shareholders at the FY 2026-2027 AGM; ~80% is tied to performance targets linked to the $320 million / Rs.3,000 crore EBITDA true north target for FY30; impact will reflect in P&L from H2 of Q3 FY 2026-2027.
• ETR at 22.1% for the combined entity — guided to remain in the 22-23% range in Q3-Q4 FY 2026-2027; balance sheet carries $123 million of intangibles and $50 million of technology (from TruBridge) to amortize, with a proportionate D&A number to be assumed for Q3 FY 2026-2027.
• ROE at 27% — which management hopes to sustain around these levels; adjusted EBITDA per employee at Rs.1.29 million in Q2 FY 2026-2027, with IKS core headcount flattish QoQ.

Top-Client Revenue Dip Explained; More One-Time Work Anticipated

• Top client revenue declined from Rs.480 Cr in Q1 FY 2026-2027 to Rs.342 Cr in Q2 FY 2026-2027 — a similar sequential pattern was visible in top 5 and top 10 client revenue (question raised by analyst Madhuchandana, MC Pro).
• CFO attributed the top-10 sequential decline to a short-term project from one of the top 5 customers — effectively replaced by customers outside the top 10, keeping overall growth at a healthy level; the short-term project revenue came from multiple clients, not a single client.
• One-time projects are seasonal value-based care initiatives — e.g., HCC coding and retrospective review of patient charts before submission to CMS with a certain code, typically arising between calendar Q3 and Q4 of any fiscal year.
• CEO anticipates more one-time work from FY 2026-2027 onward — combining technology and human capital to address short-term client needs, so one-time revenue spikes may appear in upcoming quarters.
• Management declined to quantify or guide on one-time project revenue; specifics will be discussed in future quarters as projects materialize.
• TruBridge Clearing House positioned as a modest TAM expander — at least 2-3 live proposals (as of the Q2 FY 2026-2027 call) include it, but only for new deals since legacy IKS clients are committed to other clearinghouses for the medium-to-long term; management cautions these are "very incremental numbers" given price compression and competitive intensity.